Janssen Global is a brand driven by innovation and dedicated to eliminating cancer through cancer interception. They go beyond early detection to understand why healthy cells turn cancerous, aiming to develop treatments that interrupt this process. By finding and targeting pre-malignant cells before they become aggressive and resistant to treatment, they are committed to improving outcomes for patients.

Janssen Global focuses on exploring biological precursors that can identify abnormalities before clinical symptoms appear, enabling early intervention. They have a deep understanding of the relationship between cancer cells and the tumor microenvironment, using this knowledge to play a critical role in cancer initiation, progression, metastasis, and drug resistance. They are also dedicated to localized and targeted delivery of therapy to improve outcomes in early-stage diseases like bladder cancer.

Janssen Global's commitment to innovation is exemplified by their recently acquired TARIS delivery system. With a strong emphasis on oncology, Janssen Global is at the forefront of transforming cancer treatment